Biomerica, Inc.

BMRA is still in a long recovery phase after a deep 52-week drawdown, but it has reclaimed its 200-day area and is trading above the 50-day average. The setup is constructive rather than confirmed, with the stock still well below its 52-week high and volatility remaining high for a small-cap healthcare name.

Street sentiment leans positive, with 3 buy ratings and no holds or sells, but the published target of $13 sits far above the current trading range. There have been no recent rating changes, so the bullish view is steady rather than accelerating.

The next print comes after a string of losses, with recent EPS results still negative and the company carrying a 0/2 beat rate. Shareholders should watch whether revenue growth can keep building from the latest 16.8% year-over-year pace while margins stay contained.

Recent insider activity leans supportive. The clearest signal is discretionary buying from the CEO, executive vice chairman, and directors, while the officer share entries look like award-related flows rather than fresh conviction. No notable insider selling has shown up.

Profitability remains weak, but revenue is growing and the balance sheet is not stretched. Gross margin was 8.1%, operating margin was -175.2%, and revenue rose 16.8% year over year, while free cash flow was -$3.42 million and cash of $1.308 million trailed debt of $2.383 million.

BMRA looks like a niche diagnostics name with higher risk and lower scale than larger medical device peers. The valuation still screens as speculative, with a negative earnings profile and a market cap of about $6.6 million, even as the consensus target implies substantial upside.